Previous 10 | Next 10 |
2023-06-05 07:31:25 ET Akero Therapeutics ( NASDAQ: AKRO ) added ~15% pre-market Monday after highlighting the potential of its investigational liver disease therapy efruxifermin (EFX) in combination with a popular weight loss drug class called GLP-1 receptor agonists (GLP-1). ...
Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated with EFX combined with GLP-1 had normalized liver fat at week 12, compared with 10% of those treated with...
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, June 5...
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that management will present at the Jef...
2023-05-29 15:00:00 ET The Institute for Clinical and Economic Review (ICER), the influential U.S. drug pricing watchdog, has warned about the affordability of two medications currently undergoing studies for liver disease, nonalcoholic steatohepatitis (NASH). Issuing a so-called access...
2023-05-18 02:17:39 ET Summary Strong clinical results, including significant reductions in liver fat, improvements in glycemic control, and fibrosis regression without worsening of NASH, support the efficacy and potential of EFX. Akero Therapeutics' ongoing Phase 2b and Phase 3 t...
2023-05-17 05:31:57 ET Clinical-stage company developing transformational treatments for patients with serious metabolic diseases, Akero Therapeutics ( NASDAQ: AKRO ) prices an underwritten offering of 5.24M shares at a price of $42.00 per share. Total gross proceeds of ~$...
SOUTH SAN FRANCISCO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offe...
2023-05-15 10:34:32 ET Akero Therapeutics press release ( NASDAQ: AKRO ): Q1 GAAP EPS of -$0.55. Akero's cash, cash equivalents and short-term marketable securities for the period ended March 31, 2023 were $343.2 million. For further details see: Akero Therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...